Piperlongumine induces ROS mediated cell death and synergizes paclitaxel in human intestinal cancer cells - 18/06/20
pages | 10 |
Iconographies | 9 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Three possible mode of action of Piperlongumine. (A) By increasing ROS levels (B) By inhibiting the anti-oxidant enzymes (C) By activating the SMAD4 pathway.
Highlights |
• | Piperlongumine (PL) kills intestinal cancer cells by elevating ROS levels. |
• | PL significantly up-regulates SMAD4 expression, leading to apoptosis in cancer cells. |
• | PL with Paclitaxel can be a better option for chemotherapy. |
Abstract |
Piperlongumine (PL), a herbal drug extracted from long pepper (Piper longum L), is known for its anti-inflammatory and anti-cancer properties. Although, its anti-cancer potential has been evaluated in cancer models like breast, pancreatic, gastric, hepatocellular and lung carcinoma, there is no report on its bio-activity evaluation in intestinal cancers. Here, we report the anti-neoplastic potential of PL against human intestinal carcinoma in-vitro and its possible mechanisms of action. Cytotoxicity studies demonstrate that PL inhibits cell proliferation of INT-407 and HCT-116 cells in a concentration and time-dependent manner. Also, PL elevated the levels of intracellular reactive oxygen species, which may lead to lethal oxidative stress, mitochondrial dysfunction, and nuclear fragmentation. Remarkably, P53, P21, BAX, and SMAD4 were significantly upregulated after PL treatment whereas; BCL2 and SURVIVIN were down-regulated. Moreover, the combination study also shows the synergistic effect of PL with the current chemotherapeutic drug paclitaxel. These findings suggest that PL possesses anti-neoplastic properties in intestinal cancer cells.
Le texte complet de cet article est disponible en PDF.Keywords : Piperlongumine, Smad4, Herbal medicine, Paclitaxel, Cancer, ROS
Plan
Vol 128
Article 110243- août 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?